http://www.theflyonthewall.com/perm...e-Heart-catalyst-remains-trial-says-Canaccord
Sunshine Heart catalyst remains trial, says Canaccord
Canaccord would be buyers of Sunshine Heart as their checks indicate accelerating enrollment in its pivotal U.S. study of Class lll heart failure. The firm believes the study is the most significant catalyst for the stock, as the company looks to differentiate itself with its potentially disruptive technology. Canaccord keeps its Buy rating and $10 price target on Sunshine Heart.
---------------------------------------------------------------------------------------------------------------------------------------------------------
http://www.theflyonthewall.com/permalinks/entry.php/SSHid2064116/...
Add to My Watchlist
What is My Watchlist?